Philip Morris International Inc. — FY 2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. The filing reports annual results; it does not provide a clear standalone fourth-quarter income statement. PMI sells cigarettes and smoke-free products primarily outside the United States and is pursuing a smoke-free transition, alongside expansion into wellness and healthcare.
Financial results and liquidity
| Metric | FY 2021 | FY 2020 | Change / context |
|---|---|---|---|
| Net revenues | $31.405 billion | $28.694 billion | Up 9.4%; up 6.7% excluding currency and acquisitions |
| Gross profit | $21.375 billion | $19.125 billion | Gross margin approximately 68.1%, versus 66.7% |
| Operating income | $12.975 billion | $11.668 billion | Up 11.2%; operating margin approximately 41.3%, versus 40.7% |
| Net earnings attributable to PMI | $9.109 billion | $8.056 billion | Up 13.1% |
| Diluted EPS | $5.83 | $5.16 | Up 13.0%; up 10.7% excluding favorable currency impact |
| Operating cash flow | $11.967 billion | $9.812 billion | Up $2.2 billion; capital expenditures were $748 million |
| Cash and cash equivalents | $4.496 billion | $7.280 billion | At year-end |
| Total debt | $27.8 billion | $31.5 billion | Down $3.7 billion; weighted-average financing cost 2.4% |
RRP net revenues rose to $9.115 billion from $6.827 billion; combustible-product net revenues were $22.190 billion, compared with $21.867 billion. PMI shipped 719.9 billion cigarettes and heated tobacco units, up 2.2%; heated tobacco unit shipments increased 24.8% to 95.0 billion, while cigarette shipments declined 0.6% to 624.9 billion.
Current assets were $17.717 billion and current liabilities $19.255 billion at year-end. PMI had $6.3 billion in committed credit facilities, fully available, and no commercial paper outstanding. It paid $7.6 billion in dividends and repurchased $785 million of shares in 2021. Total stockholders’ deficit was $8.208 billion.
Material changes and business developments
- Growth was led by smoke-free products, favorable pricing and recovery in some combustible markets from pandemic-affected 2020 levels. Higher heated tobacco volume supported revenue and operating income; foreign currency also benefited reported results.
- Regional performance was mixed: EU revenue increased to $12.275 billion and operating income to $6.119 billion; South & Southeast Asia operating income declined to $1.506 billion from $1.709 billion, with revenue flat at $4.396 billion.
- PMI acquired Vectura and Fertin Pharma, expanding into inhaled therapeutics and oral delivery systems, and acquired OtiTopic. The acquisitions used $2.111 billion of cash, net of acquired cash. The new “Other” category recorded $101 million of revenue and a $52 million operating loss, including a $51 million OtiTopic in-process R&D charge.
- Saudi Arabia customs assessments resulted in a $246 million reduction in 2021 net revenues and a $0.14 diluted EPS charge. 2020 included a $119 million Brazil indirect-tax credit; 2021 included $216 million in asset impairment and exit costs, versus $149 million in 2020.
Outlook, risks and contingencies
- Management expects IQOS device supply to improve and user growth to return gradually toward an unconstrained progression, but said it lacked full visibility for 2022. The filing gives no clear full-year revenue or EPS guidance. It estimates a 2022 effective tax rate of about 22%, excluding discrete tax events, and capital expenditures of approximately $1.0 billion.
- An ITC importation ban and cease-and-desist orders affecting IQOS Platform 1 products in the United States took effect in November 2021; IQOS was no longer available for sale in the U.S. PMI appealed and cited contingency plans, including domestic production, while hoping to resume U.S. supply in the first half of 2023.
- Key risks include tobacco regulation and excise taxes, declining cigarette consumption, adoption and regulatory treatment of RRPs, semiconductor and device supply constraints, COVID-19 disruption, currency volatility, illicit trade, and acquisition integration and impairment risk.
- PMI disclosed significant tobacco-related litigation. For pending smoking-and-health class actions and health-care cost recovery cases, management had not concluded a loss was probable and could not estimate a possible loss range; no estimated loss was accrued, except as otherwise disclosed. The Canadian tobacco litigation remains subject to CCAA proceedings and a stay.
- Other notable exposures include a $260 million Indonesian tax assessment paid while under objection, and a Medicago guarantee whose maximum amount PMI said was not estimable; PMI stated the guarantee had no material financial-statement impact at year-end.
Important facts for investors to verify
- Whether RRP revenue and heated tobacco unit growth can continue as device supply improves, and whether margins remain supported by pricing and productivity.
- Developments in the U.S. IQOS ITC appeal, domestic-production plans, and the timing and terms of any resumption of U.S. sales.
- Acquisition integration, purchase-price allocation and subsequent results for Vectura and Fertin, as well as progress and contingent costs for OtiTopic.
- Potential cash, earnings or liquidity effects from tobacco litigation, customs and tax disputes, including the Canadian CCAA process and Saudi assessments.
- Debt maturities, dividend and repurchase commitments, and the impact of cash balances and short-term obligations on liquidity.